LadRx (LADX) Interest Coverage

: No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. LadRx's Operating Income for the three months ended in Dec. 2023 was $-0.88 Mil. LadRx's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. LadRx has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. LadRx Corp has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for LadRx's Interest Coverage or its related term are showing as below:

LADX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt Med: No Debt Max: No Debt
Current: No Debt

LADX's Interest Coverage is ranked better than
99.15% of 353 companies
in the Biotechnology industry
Industry Median: 144.99 vs LADX: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LadRx Interest Coverage Historical Data

The historical data trend for LadRx's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

LadRx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Coverage

No Debt

N/A

No Debt

LadRx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Coverage																N/A	No Debt	No Debt	No Debt	No Debt

Competitive Comparison

For the Biotechnology subindustry, LadRx's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LadRx Interest Coverage Distribution

For the Biotechnology industry and Healthcare sector, LadRx's Interest Coverage distribution charts can be found below:

* The bar in red indicates where LadRx's Interest Coverage falls into.

LadRx Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage

-1

Operating Income

Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt ⁽¹⁾.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

LadRx's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, LadRx's Interest Expense was $0.00 Mil. Its Operating Income was $-3.82 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

LadRx had no debt ⁽¹⁾.

LadRx's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Here, for the three months ended in Dec. 2023, LadRx's Interest Expense was $0.00 Mil. Its Operating Income was $-0.88 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

LadRx had no debt ⁽¹⁾.

The higher the ratio, the stronger the company's Financial Strength is.

LadRx (OTCPK:LADX) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .

LadRx Interest Coverage Related Terms

Thank you for viewing the detailed overview of LadRx's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.

LadRx (LADX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (OTCPK:LADX) » Definitions » Interest Coverage

Comparable Companies

Traded in Other Exchanges

N/A

Address

11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049

Website

https://www.ladrxcorp.com

LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

Executives

Cary J Claiborne	director	3056 SENECA CHIEF TRAIL, ELLICOTT CITY MD 21042
Stephen Snowdy	officer: Chief Executive Officer	C/O CYTRX CORPORATION, 11726 SAN VICENTE BOULEVARD, SUITE 650, LOS ANGELES CA 90049
Jennifer K. Simpson	director	C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Eric Curtis	officer: Pres., Chief Operating Officer	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Felix Kratz	officer: Vice President Drug Discovery	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joel K Caldwell	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Chawla Shanta M.d.	officer: Senior VP-Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Earl W Brien	director	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Olivia C Ware	officer: Chief Commercial Officer	11726 SAN VICENTE BLVD, SUITE 650, LOS ANGELES CA 90049
Cheryl Cohen	director	C/O MEDIVATION, INC., 201 SPEAR ST., 3RD FLOOR, SAN FRANCISCO CA 94105
Eric Jay Selter	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Anita J Chawla	director	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Joseph Rubinfeld	director	C/O SUPERGEN INC, 4140 DUBLIN BLVD STE 200, DUBLIN CA 94568
Douglas Scott Wieland	officer: Sr VP - Drug Development	11726 SAN VICENTE BLVD., SUITE 650, LOS ANGELES CA 90049
Louis Ignarro	director	11726 SAN VICENTE BLVD, STE 650, LOS ANGELES CA 90049